DarioHealth (Nasdaq:DRIO) announced today that multiple research studies support its digital therapeutics for diabetes management.
New York-based DarioHealth presented the data from the new studies at the American Diabetes Association’s (ADA) 82nd Scientific Sessions in New Orleans. Two of the studies add to DarioHealth’s evidence supporting an integrated approach to managing multiple chronic conditions, while the third analyzed the impact across ethnicities of users living with type 2 diabetes.
According to the release, one study examined a group of users with diabetes and stage 1 and above hypertension to understand the impact of using a single solution on both conditions. Results demonstrated significant improvements for both hypertension and diabetes at six months.
Get the full story at our sister site, Drug Delivery Business News.